Page last updated: 2024-10-15

collismycin b

Description

collismycin B: glucocorticoid receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135474257
CHEMBL ID1834106
SCHEMBL ID2631460
MeSH IDM0237634

Synonyms (9)

Synonym
collismycin b
CHEMBL1834106
158792-25-7
(2,2'-bipyridine)-6-carboxaldehyde, 4-methoxy-5-(methylthio)-, oxime, (z)-
sf 27388
SCHEMBL2631460
collismycin
(nz)-n-[(4-methoxy-3-methylsulfanyl-6-pyridin-2-ylpyridin-2-yl)methylidene]hydroxylamine
(e)-4-methoxy-5-(methylthio)-[2,2'-bipyridine]-6-carbaldehydeoxime
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID621488Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Coprismycins A and B, neuroprotective phenylpyridines from the dung beetle-associated bacterium, Streptomyces sp.
AID621492Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation at 50 uM2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Coprismycins A and B, neuroprotective phenylpyridines from the dung beetle-associated bacterium, Streptomyces sp.
AID621493Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation at 50 uM2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Coprismycins A and B, neuroprotective phenylpyridines from the dung beetle-associated bacterium, Streptomyces sp.
AID621487Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Coprismycins A and B, neuroprotective phenylpyridines from the dung beetle-associated bacterium, Streptomyces sp.
AID621490Cytotoxicity against human AGS cells assessed as inhibition of cell proliferation2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Coprismycins A and B, neuroprotective phenylpyridines from the dung beetle-associated bacterium, Streptomyces sp.
AID621491Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Coprismycins A and B, neuroprotective phenylpyridines from the dung beetle-associated bacterium, Streptomyces sp.
AID621495Cytotoxicity against human AGS cells assessed as inhibition of cell proliferation at 50 uM2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Coprismycins A and B, neuroprotective phenylpyridines from the dung beetle-associated bacterium, Streptomyces sp.
AID621489Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Coprismycins A and B, neuroprotective phenylpyridines from the dung beetle-associated bacterium, Streptomyces sp.
AID621496Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation at 50 uM2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Coprismycins A and B, neuroprotective phenylpyridines from the dung beetle-associated bacterium, Streptomyces sp.
AID621494Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation at 50 uM2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Coprismycins A and B, neuroprotective phenylpyridines from the dung beetle-associated bacterium, Streptomyces sp.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]